Biologics have revolutionized the therapy of the psoriatic disease spectrum. These new classes of drugs also allow deeper insight into the pathogenesis of the disease and highlight the existence of distinct ''molecular'' disease subgroups as evidenced by the spectrum of clinical response seen. Molecules associated with both the interleukin (IL)-17 and interferon (IFN)c pathways have important functions in psoriatic inflammation, and both are targeted by drugs acting on the p40 subunit shared by IL-12 and IL-23. These IL-12 family members are upstream of pathways characterized by the production of IFNc and IL-17 related molecules, including IL-17, IL-22, and CCL20. We here summarize the mode of action and clinical studies of the p40 inhibitor ustekinumab with focus on both psoriasis and psoriatic arthritis.
INTRODUCTION
The pathogenesis of the psoriatic disease spectrum involves a plethora of cells and mediators. Given the complexity of the skin cytokine network, the cross regulation between infiltrating leukocyte subsets, endothelial cells and tissue resident mesenchymal and epithelial cells as well as tissue resident immune cells including innate leukocyte cell (ILC) subsets, it seems surprising that disease symptoms are responsive to a relatively wide array of interventions. In particular, patients with psoriasis respond to treatment interfering with lymphocyte activation, the tumor necrosis factor (TNF) pathway, agents blocking interleukin (IL)-17 or the IL-12/23p40 subunit.
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The reason for different pathway blockage to work therapeutically in psoriasis lies most probably in their synergistic action which ultimately drives psoriatic inflammation.
Synergistic activity regarding cell activation and cytokine production has been highlighted in a large number of studies mainly based on in vitro work. Very potent ''mediator combinations'' which can cause significant activation and proliferation/differentiation responses in the skin compartment are, for example, TNF ? IL-17, IFNc ? TNF, and
IFNc ? IL-17 [1] . Enhanced pro-inflammatory properties have also been described for the combined action of IL-22, IL-17, TNF, and IFNc both in the skin and synovial compartment. The p40 unit shared by IL-12
and IL-23 is a fascinating therapeutic target as it influences two important effector cytokines, IFNc and IL-17, the production of which is regulated by IL-12 and IL-23, respectively.
Ustekinumab (UST) is a monoclonal antibody which targets the p40 subunit shared by IL-23
and IL-12.
THE ROLE OF IL-12/23 IN INFLAMMATORY IMMUNE RESPONSES
The p40 b-chain can pair with the p35 or p19 subunit to form the heterodimeric cytokine IL-12 or IL-23, respectively. IL-12 and IL-23 are members of the IL-12 family along with IL-27 and IL-35 (for a review see [2] ). The p35 subunit of IL-12 is expressed ubiquitously whereas p40 expression largely restricted to antigen presenting cell (APC) types. Although p40 homodimers have been described for their antagonistic action on IL-12/IL-23, this has not been convincingly shown in the human system. The p19 and p35 on their own are biologically inactive. IL-12 and IL-23 each bind to a two-subunit receptor complex. They share the IL-12Rb1 receptor but differ regarding signaling pathway activation by binding to the high affinity IL12Rb2, which is highly expressed on type 1 cells (including T helper (Th) cells type 1 and ILC1) and IL-23R, respectively. IL-23R is one of the susceptibility genes highlighted by genome-wide association studies for both psoriasis and psoriatic arthritis (PsA) as is IL12B, which encodes for p40 [3] . IL-23 and IL-12 can both activate molecules of the same signaling pathways and these include JAK2, TYK2, STAT1, STAT3, STAT4, and STAT5. However, IL-12 predominantly signals via STAT4 phosphorylation, whereas IL-23 has a stronger impact on STAT3 pathway activation.
There is a positive feedback loop in that STAT3 pathway activators (e.g., IL-23, IL-6, OSM, IL-22) can upregulate the cell surface expression of IL-23R; similarly STAT4 activation leads directly and indirectly via IFNc secretion on IL-12Rb2 expression [4] . Importantly high expression of IL-12Rb2 is also influenced by IL-18 and by type I IFNs, which are highly expressed in psoriatic inflammation. IL-12, which is mainly produced by macrophages and dendritic cells (DC), is a crucial molecule for polarization of CD4? cells along the Th1 lineage [5, 6] . It is also well described for its action on cytotoxic CD8? T lymphocytes and natural killer (NK) cells which ultimately can lead to their enhanced cytotoxicity. By acting on NK, CTL, Th1, and ILC type 1 the presence of IL-12 will lead to production of IFNc. In the context of skin inflammation, and in particular psoriasis, it is of interest that IL-12 can induce the expression of cutaneous lymphocyte antigen (CLA) on lymphocytes [7, 8] . This homing receptor is responsible for directing lymphocyte trafficking into the skin.
Regarding T cell differentiation, IL-12 also has strong antagonist actions on Th2 pathway polarization [9] and the class switch towards immunoglobulin (Ig) E. IL-12 has also been described for its inhibitory impact on retinoic acid receptor-related orphan receptor-cT (RORcT), a key transcription factor for Th17 polarization. As a result, IL-12 can act on differentiating human Th17 cells to switch them to more IFNc production.
Main Actions of Importance for Psoriasis
IL-12 is key for the production of INFc which is one of the strongest activators of keratinocyte proinflammatory responses ( Fig. 1 ). IFNc induces the production of CXCL10 in keratinocytes, which attracts even more CXCR3 ? IFNc producing T cells. Similar mechanisms are in place on the level of the synovium. The proinflammatory properties of both IL-12 and IFNc can be enhanced by TNFa.
IL-12 can furthermore play a role in the homing of lymphocytes into the skin by virtue of its action on CLA expression. IL-23 is also mainly produced by activated APCs (macrophages, DCs) [10] . IL-23 was only described a number of years after IL-12 and many of the early studies which measured IL-12p40 did not distinguish between IL-23 and IL-12 functional effects. All initial data on IL-23 highlighted this cytokine as inducer of IFNc production, a strong positive feedback loop supporting ''type 17 inflammation'' is created which plays an important role in chronic psoriatic inflammation. IL-1 and IL-23 act in synergy to induce local tissue inflammation and IL-23 increases the cellular sensitivity to IL-1 by acting on its receptor expression.
Actions of IL-23 will ultimately lead to IL-17 production and support the survival and via CCL20 the recruitment of type 17 cells ( Fig. 1 ). Those cells also produce IL-22. Both IL-22 and IL-17 directly activate keratinocytes but also synovial cells. IL-17 and TNF show synergistic 
MAIN FUNCTION OF IL-12/23P40 BLOCKADE IN PSORIASIS
This therapeutic intervention can act on many different levels as highlighted above. Reducing the proinflammatory actions of the effector cytokines IFNc and IL-17/IL-22 seems key. However, there is also some counter-regulation between type 1 and type 17 cells. Depending to the ''molecular'' subtype of psoriasis or the disease to be treated, breaking this counter regulatory balance could, to some extent, lead to ''weakening'' of the antiinflammatory action of the inhibitor. On the other hand, in theory, higher availability of p35 subunit (although widely expressed) could lead to increase in the regulatory IL-12 family member IL-35 which is a p35/EBI3 heterodimer; however, this remains to be shown. Fig. 1 Schematic, simplified overview of IL-12/IL-23 dependent action on molecules involved in psoriatic inflammation. Only positive/activating pathways are depicted. Both IL-12 and IL-23 are produced by activated APCs including macrophages. Upon receptor ligation, these heterodimeric cytokines activate the Stat4/3 pathways ultimately resulting in upregulation of cell surface receptors and secretion of cytokines. Of importance, type 17 cells, which are dependent on IL-23 stimulation, express high levels of CCR6 which enables the cell to follow a chemokine gradient build by CCL20 which is produced by IL-17/IL-22 stimulated keratinocytes. Thus type 17 cells will home into CCL20 rich tissues. On the other hand, IL-12, via activation of Stat4, acts on expression of the skin homing receptor CLA but also CXCR3 which interacts with the chemokines CXCL9, 10, 11 which are all highly expressed by keratinocytes which have been exposed to IFNs. IFNc is one of the strongest priming signal for APC to induce the production of the IL-12 family members IL-12 and IL-23. Negative regulatory feedback actions are not depicted in this figure. However, there is significant negative cross-regulation between type 1 and type 17 cells. Blocking the p40 subunit of both IL-12 and IL-23 could therefore result in ' 'paradoxical'' effects where this negative regulatory influence plays an important role in disease pathology. APC Antigen presenting cell, CLA Cutaneous lymphocyte antigen, IFN Interferon, IL Interleukin
IL12/23 Inhibitors in Other Dermatologic

Diseases
Sarcoidosis is a disease with high IL-12 activity. Both the p40 subunit as well as the expression of the high affinity IL-12Rb2 has been found increased in this disease. While there are reports on successful treatment of sarcoidosis with UST there is also a case report suggesting a paradoxical sarcoidosis promoting effect under p40 inhibition, similar to what has been reported for TNF blockade [13] . A recent study on skin and lung sarcoidosis patients suggests that blockage of TNF may result in more favorable therapeutic effects for the skin than that of p40 blockade for the time period observed [14] . Case reports suggest that UST could be of benefit in therapy resistant Pyoderma gangrenosum [15, 16] , hidradenitis suppurativa [17, 18] , SAPHO syndrome [19] , and pityriasis rubra pilaris [20] [21] [22] [23] .
CLINICAL STUDIES IN PSORIASIS
In January 2009, UST (CNTO 1275, Stelara; Janssen Cilag) was granted marketing authorization by the European Commission for the treatment of moderate to severe chronic plaque psoriasis in adults who failed to respond to, who have a contraindication to or who are intolerant of systemic oral immunosuppressants.
Unlike the other biological anti-psoriatic agents already brought to market, which all targeted TNFa, UST was the first-in-class anti-IL agent for psoriasis, representing an important milestone in rational drug design. UST is a fully human IgG1j monoclonal antibody that inhibits IL-12 and IL-23 activity by binding with high affinity and specificity to their shared p40 subunit. IL-12/23 bioactivity is thus inhibited by preventing their binding to IL-12 receptor b1
(IL-12Rb1) on the surface of immune cells.
Phase I and II Clinical Trials
UST's therapeutic potential was apparent in early phase I studies, with reductions in lesional gene expression of IL-12p40, IL-23p19 and other inflammatory cytokines as early as two weeks post treatment [24] [25] [26] . The drug was well tolerated and appeared to have low immunogenic potential. In some patients, a single intravenous or subcutaneous dose resulted in a rapid and marked clinical response that was sustained for 16-24 weeks. In an initial phase II randomized trial [27] , 320 patients were allocated to one of five groups, receiving placebo or one of four doses of UST (45 regained their PASI 75 after 12 weeks of retreatment [28] .
Expanding on the initial PHOENIX I trial data reported at week 76, all patients were subsequently followed to week 244 (5 years) to assess longer-term safety and efficacy [31, 32] . Overall, 68.7% (n = 517) of the initial overall population of 753 (who had received at least one dose of UST in PHOENIX I) were evaluated. [32] .
Nail involvement may be present in up to 80% of patients with psoriatic disease and is notoriously difficult to treat, leading to high psychosocial embarrassment [33] and in severe cases, functional limitation [34] . Improvements in fingernail psoriasis were assessed in the PHOENIX I cohort using the Nail Psoriasis Severity Index (NAPSI) on a target fingernail in addition to a nail PGA and assessment of the mean number of nails involved [35] . The second large phase III clinical trial,  PHOENIX II, recruited 1,230 patients and 61% were either non-responsive to, intolerant of or had a contraindication to other systemic therapy [29] . Like PHOENIX I, patients were randomized to one of three arms; 45 mg or 90 mg subcutaneously at week 0, 4 and every 12 weeks, or placebo at weeks 0 and 4 and then crossover to active therapy ( response was achieved, but this was not the case for those receiving 45 mg [29] .
In terms of safety, both PHOENIX I and II reported similar outcomes during the placebocontrolled phase. Adverse events occurred in 278 (54.5%) of the 510 patients receiving UST in PHOENIX I [28] and 414 (50.5%) of 820 patients in PHOENIX II [29] . This is compared with 48.2 and 49.8% in their respective placebo groups.
Serious adverse events occurred in similar proportions in both trials and with similar low
frequencies between the UST and placebo treated arms (1.2% UST vs. 0.8% placebo in PHOENIX I; 1.6% UST vs. 2.0% placebo in PHOENIX II). In PHOENIX I, the pattern of adverse events was much the same in the placebo crossover and randomized withdrawal phases as it was in the placebo-controlled phase [28] . Rates of antibody formation to UST were found in 5.1% of patients by the end of week 76 (PHOENIX I) and 5.4% of patients by the end of week 52 (PHOENIX II), and in both trials, these were mostly of low titer.
The ACCEPT phase III clinical trial differed from the PHOENIX trials in that the safety and efficacy of UST were compared with an active comparator (etanercept) rather than placebo [30] . In this 64 week trial, 903 patients were randomized (3:5:5 ratio) to receive subcutaneous injections of UST (45 or [39] . Genetic susceptibility to psoriasis can vary between races, although Chiu et al. [40] replicated the Italian study in Chinese patients with psoriasis. In addition to genetic factors, obesity has been recognized as an important factor related to both the incidence and severity of psoriasis [41] . affected by weight, and together these findings provided the rationale for the higher dose subsequently licensed for patients weighing more than 100 kg [43] .
Quality of Life Response
In PHOENIX I, more than 97% of patients had a score of 1 or more on the DLQI at baseline, and the average score was greater than 10 out of a possible maximum of 30, indicating a significant impact on patients' quality of life [44] Sexual difficulties were specifically analyzed from the DLQI data collated in both PHOENIX I and II [46] . Impaired sexual function was recorded if any patient scored 'very much' or 'a lot' for question 9 of the DLQI. 27.1% of women and 20.8% of men reported impaired sexual function at baseline, and this was significantly associated with increased psoriasis severity. At week 12, the overall proportion of patients with sexual difficulties decreased from 22.6 to 2.7%, compared to no change in the placebo arm (P\0.001). Patients with a greater mean improvement in PASI score experienced a greater reduction in sexual difficulties caused by psoriasis.
CLINICAL STUDIES IN PSA
For UST, in PsA, the main phase III studies are PSUMMIT-1 (ClinicalTrials.gov #NCT01009086) [47] and PSUMMIT-2 (ClinicalTrials.gov #NCT01077362) [48] . reported. Of note, three major cardiovascular events occurred in the UST groups in the first 30 weeks of treatment.
Patients in PSUMMIT-1 were TNFi naïve. PSUMMIT-2 addressed the issue of previous TNFi exposure. Although a similar design was employed (same criteria for active disease, randomization and early escape, stratification for weight and MTX use) just over half of the 300 patients recruited had prior TNFi exposure. Of these TNFi experienced patients the majority had used more than one agent and 70% had discontinued the drug because of inadequate response. In PSUMMIT-2 the primary end-point of superiority over placebo at week 24 was reached despite the more challenging patient population and the smaller sample size ( Table 1) .
As expected response rates in those patients who were TNFi experienced were inferior to TNFinaïve patients. Of interest, results were independent of MTX usage and, generally, weight, although response was not as good in patients over 100 kg in the UST 90 mg group. As with PSUMMIT-1 improvement was seen in skin, enthesitis, BASDAI in patients with spinal inflammation, fatigue, and function but not for dactylitis. No major MACE events were seen up to week 16 but up to week 60 the myocardial infarction rate was 0.74/100 patient years.
In order to achieve a sufficient sample size, structural progression analyses were prespecified for a pooled analysis of PSUMMIT-1 and PSUMMIT-2 patients [49] . 
DISCUSSION
UST is a new class of drug specifically targeting the IL-12/23 axis and is effective in psoriasis and
PsA. What is the likely use of this drug in clinical practice? It is worth considering the current treatment algorithms in use in this TNFi for the articular manifestations. However, only head-to-head data will be able to confirm this observation given the possible disparity of patient populations across the studies.
Nevertheless, UST, like TNFi is effective for all aspects of the disease, skin and musculoskeletal and, from a patient point of view this is an attractive feature.
The kinetics of response may be of some concern. If a rapid response of skin and joints is required then the physician is more likely to recommend a TNFi, or one of the IL-17 inhibitors. On the other hand, if there has been TNFi failure, then UST may be an attractive option, given the results of the PSUMMIT-2 study. More data is needed on the response to UST according to primary or secondary non-response to TNFi-it is likely these data are available from the PSUMMIT-2 study and will no doubt appear in due course.
The 52 week results also suggest that alternative dosing schedules may be required for articular and other musculoskeletal manifestations, possibly with a shorter dosing interval.
UST will have a place in treatment when
TNFi are contra-indicated (currently with a history of demyelinating disorder, active tuberculosis, or a recent malignancy) although it must be emphasized that we still do not know the safety of UST in these situations. A doubt still remains about MACE events with UST and only long term surveillance using registry data will be able to illuminate this and other safety concerns.
Should UST be co-prescribed with MTX? The studies so far do not indicate any enhancement of efficacy with MTX use but, as with TNFi, MTX may prolong the effective period of this drug, although the rate of antibody formation to UST seems low. However, many patients find the higher doses of MTX unacceptable so it would be prudent to use a low maintenance dose of 10-15 mg.
CONCLUSION
UST provides another weapon in the physicians armory, with a new target. Cost issues will be equivalent to TNFi and other biologics so its place in the treatment algorithm of psoriasis and PsA will evolve over time and with continued use. The different mode of action will offer a treatment alternative to TNFi failures but the rather slow onset of action may be a problem for some patients and their physicians. 
